Skip to main content
No adverse impact of infliximab biosimilar switch on IBD control or drug levels
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
No adverse impact of infliximab biosimilar switch on IBD control or drug levels
User login
Username
Password
Reset your password
Concept
Lead
score
Inflammatory Bowel Disease
1
0.97
Biologic Therapy
0
0.81
Biosimilars
0
0.81
Remission
0
0.49
Biomarker
0
0.16
Colitis
0
0.16
Grant
0
0.16
Pain
0
0.16
Pain Management
0
0.16
Specialty
Lead
score
Gastroenterology
1
1
Nursing
0
0.91
Pharmacist
0
0.91
Family Medicine/Primary Care
0
0.28
Internal Medicine
0
0.28
Anesthesiology
0
0.16